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ABSTRACT
Coronavirus disease 2019 (COVID-19) is the disease caused by the highly transmittable novel
coronavirus (SARS-CoV-2) infections. The disease was found at the end of December 2019,
in Wuhan, China, and quickly spread worldwide with a higher mortality rate compared to the
previous coronavirus disease. Cytokine plays an important role in the inflammatory response
against coronavirus infection. However, in severely ill patients with COVID-19, an excessive
amount of cytokine serum level (cytokine storm) has been associated with the aggravation
of coronavirus disease leading to acute respiratory distress syndrome (ARDS). Thus, the
management of the cytokine storm could be the key to stop COVID-19 progression. This article
reviews an overview related to SARS-CoV-2 and COVID-19, mechanism and prospective
treatment strategies for cytokine storm in COVID-19, and a viewpoint of stem cells perspective.
The purpose is to provide some information that could be useful for future guidelines in the
clinical management of COVID-19.
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INTRODUCTION
Coronavirus disease 2019 (COVID-19) was initially
emerged in Wuhan, China, in December 2019, and
rapidly spread worldwide owing to the explosion of
cases. The disease is caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) that highly
transmittable (Lai et al., 2020). As of 15 June 2020, a
total of 7,823,289 cases have been reported confirmed
for SARS-CoV-2 infection globally, with 431,541 deaths
related to COVID-19 (World Health Organization,
2020). The severity of the disease is widely ranged.
Some people showed asymptomatic and appeared mild
condition, flu-like symptoms, such as fever, dry cough,
fatigue, or muscle soreness. However, infected patients
could develop to critically ill and even resulting in
death. The acute respiratory distress syndrome (ARDS),
pneumonia, and multiple organ dysfunction are believed
to be some of the severe clinical manifestations of
COVID-19 progression (Ye et al., 2020; Singhal, 2020).
It has been well understood that cytokine plays
an important role in the immune response, e.g.,
as a defensive mechanism against viral infection
(Shimabukuro-Vornhagen et al., 2018). However, the
aggravation of the SARS-CoV-2 infection led to the
release of excess cytokine (cytokine storm), which could
develop into pneumonia (Sun et al., 2020). Of interest,

the cytokine storm plays a crucial role in causing ARDS
and functional derangement of multi-organ because of
an excessive immune response (Chousterman et al.,
2017), and it has been reported to be present in critically
ill patients with COVID-19 (C. Huang et al., 2020).
Therefore, controlling or suppressing the cytokine
storm in COVID-19 becomes one of the management
strategies to prevent COVID-19 progression and save the
patient’s life. This article reviews the current literature
of COVID-19 and SARS-CoV-2, its association with
cytokine storm, and current and stem cell-based
treatment strategies to inhibit the cytokine storm in
patients with COVID-19. This review aimed to provide
a useful information for the development of guidance in
clinical diagnosis and treatment of COVID-19.
METHODS
Literature studies were conducted to access Englishlanguage articles that contain information about
COVID-19 using Google Scholar, ScienceDirect, and
PubMed engine search from the NCBI database during
June 2020. COVID-19, SARS-CoV2, stem cells, and
cytokines storm were used as the keyword for engine
searching. The information about an ongoing clinical trial
related to COVID-19 was accessed from ClinicalTrials.
gov and NIH.gov.
E-ISSN 2477-0612
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The Clinical Manifestation of SARS-CoV-2 Infection
SARS-CoV-2 belongs to the Coronaviridae family in
the Nidovirales order (Shereen et al., 2020), along with
other highly pathogenic coronaviruses, which are severe
acute respiratory syndrome coronavirus (SARS-CoV)
and Middle East respiratory syndrome coronavirus
(MERS-CoV) (Ye et al., 2020). Coronavirus is singlestranded RNA viruses, size ranging from 26 to 32 kbs in
length, and Corona represents crown-like spikes on the
outer surface of the virus (Shereen et al., 2020).
The first case of highly pathogenic coronavirus is SARS
caused by SARS-CoV started in Guangdong, China, in
2002. The SARS spread around the globe and infected
more than 8000 individuals and 774 deaths. Later in
2012, another coronavirus, MERS-CoV, reemerged in
Saudi Arabia, with a total of 2428 infected individuals
and 838 deaths were reported. Genetic characterization
revealed that at the nucleic acid level, SARS-CoV-2 has
78% similarity with SARS-CoV and 50% with MERSCoV (Lu et al., 2020; Shereen et al., 2020). Hence,
patients infected by SARS-CoV, MERS-CoV, and SARSCoV-2 showed similar severe symptoms that could
lead to pneumonia, followed by ARDS and multiple
organ failure (Ye et al., 2020). In COVID-19 patients,
the major syndrome is fever, cough, lymphocytopenia,
and myalgia or fatigue (Guan et al., 2020; C. Huang
et al., 2020; R. Huang et al., 2020). Patient with preexisting metabolic condition (R. Huang et al., 2020) and
or elderly is reported to be prone to develop breathing
difficulty which might lead to ARDS and result in a
fatality (C. Huang et al., 2020).
It has been reported that bats are possible to be the
critical host transmitting medium of the virus. However,
the spreading of the virus from human to human arise
as a result of direct contact with infected individuals
exposed to coughing, sneezing, respiratory droplets, or
aerosols and penetrate via inhalation (Shereen et al.,
2020). Recent studies revealed that both SARS-Cov and
SARS-CoV-2 utilize the spike glycoprotein (S protein)
on its viral envelope to bind to angiotensin-converting
enzyme 2 (ACE2) receptor which is expressed on the
surface of human cells (Hoffmann et al., 2020; Hofmann
& Pöhlmann, 2004). The virus needs to attach to the
host cells membrane to enter the host cells and proceed
to the replication, resulting in viral infection to humans.
Of note, the ACE2 receptor is widely expressed in
various human cells with macrophages. It is thought
to be the essential target cells for coronavirus infection
(Hamming et al., 2004), hence partially explain the
COVID-19 syndrome and the development of ARDS.
The current diagnosis of COVID-19 relies on SARSCoV-2 RNA detection in nasopharyngeal swab
specimen by real-time polymerase chain reaction (RTE-ISSN 2477-0612
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PCR) or antibody test, epidemiological history, clinical
manifestations, and chest imaging (Guan et al., 2020;
C. Huang et al., 2020). Until June 2020, no approved
therapy could reliably cure COVID-19.
Ongoing Cinical Trials For COVID-19 Vaccine
To date, there are no approved vaccines or treatments for
COVID-19 (National Institutes of Health, 2020). Hence,
multiple biotechnology institutes and pharmaceutical
companies in various countries are now trying to
develop the vaccines, and some of them have been
known registered for the study of the clinical trial. For
example, the Institute of Biotechnology, Academy of
Military Medical Sciences, PLA of China is developing
the Ad5-nCoV vaccine, which is now entering Phase II of
clinical trials (NCT04341389), the ModernaTX, USA is
developing the mRNA-1273 vaccine, which is now also
entering early Phase II of clinical trials (NCT04405076),
and the University of Oxford, U.K. is developing the
ChAdOx1 nCoV-19 vaccine, which is now entering
phase II/III of clinical trials (NCT04400838) (U.S.
National Library of Medicine, 2020). However, the
world still needs to wait for another couple of months
or even years before the vaccines are ready to be
widely deployed. While waiting for the vaccines ready
to prevent a future outbreak, finding the best treatment
in reducing morbidity and mortality of COVID-19
patients are also urgently required. Many clinical trials
are now actively conducted worldwide in evaluating
the potential therapeutic agents for COVID-19 from
currently available agents such as the existed antiviral
drugs, the convalescent plasma from recovered COVID19’s patients, and the cytokines inhibitors, which is the
focus of this review.
Sars-CoV-2 Infection Leads to Cytokine Storms
Clinical data from severe COVID-19 patients have
suggested that the fatal outcome of ARDS caused by
SARS-CoV2 infection often results from alveolar injury
in the lung and lead to the respiratory and multiple organ
failures (Mehta et al., 2020; Sanders et al., 2020). The
clinical studies further found that those conditions are
associated with the significant increment of cytokine
production in the body, which also termed as cytokine
release syndrome (CRS) or cytokine storm (Ye et al.,
2020). Cytokines, the small proteins, play an essential
role in the immune response to inflammation and
infection in the body. However, the overproduction of
cytokine may cause tissue damages as the compensation
of excessive response immune.
The pro-inflammatory responses were reportedly
involved in the pathogenesis of coronavirus (SARS-CoV,
MERS-CoV, and SARS-COV-2) in severely ill patients
as the ARDS to be the leading cause of death (Lau et al.,
2013; Law et al., 2005; Mehta et al., 2020). Some studies
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explained that at the early stage of infection, delayed
release of cytokines and chemokines occurs. Later,
interferons (IFNs) were produced at a low level and
following by a rapidly high level of pro-inflammatory
cytokines and chemokines to attract the inflammatory
cells, resulting in excessive infiltration into lung tissue
and causing injury (Cheung et al., 2005; Ye et al., 2020).
Therefore, it is suggested that the inflammatory cells
may be involved in lung pathology. In the animal study,
the rapid replication of SARS-CoV led to the delayed
released of IFNs and accompanied by the accumulation
of pathogenic inflammatory mononuclear macrophages
(IMM). Further, signals were activated, and infected cells
produced chemokines to attract more IMM, resulting
in an abnormally high level of many pro-inflammatory
cytokines and thus aggravating the disease. In the later
phase, the IFN-I and other pro-inflammatory cytokines
render the T cells apoptosis, obstructing the viral
clearance (Channappanavar et al., 2016).

pro-inflammatory cytokines and IFN response in aging
may be responsible for the pathogenesis of disease (Park
& Iwasaki, 2020).

IFN-α and IFN-β, the subtypes of IFN-I, are being
essential as the first line defender against viral infection
through the Janus kinase/signal transducers and
activators of transcription (JAK-STAT) pathway (Song
et al., 2020). Coronavirus infection could induce a
significant but delayed response of IFNs and later trigger
high level of cytokines and chemokines, resulting in
cytokine storm that rapidly aggravates the disease in
severe condition (Ye et al., 2020). The delayed response
has been explained by various mechanisms.
The coronavirus encodes protein NSP1, the viral nonstructural protein 1, that hinders the phosphorylation of
STAT1, thus inhibiting the IFNs secretion (Narayanan et
al., 2008). STAT1 is known as the transcription factor
for interferon-stimulated genes (ISGs) in the antiviral
defense program (Wathelet et al., 2007). The structural
protein M (membrane) and N (nucleocapsid) encoded by
a coronavirus, also could inhibit the IFNs signaling by
interfering IRF3, the transcription factor for IFN genes
(Park & Iwasaki, 2020). Moreover, a study revealed
that SARS-CoV-2 infection released a low IFN-I during
the earlier phase while later inducing pro-inflammatory
cytokines. COVID-19 patients showed a high level of
pro-inflammatory cytokines and chemokine despite
undetectable levels of IFN-I (Blanco-Melo et al., 2020).
The high level of IFNs was found correlated with disease
severity, with mostly detected in severe patients (Park &
Iwasaki, 2020). It is suggested that the IFNs response
may be delayed, supported by in vivo study, IFN-I
was not detectable until several hours after viral load
(Channappanavar et al., 2016). The defect or suppression
of IFN induction is related to the age of hosts and caused
by the proteolytic degradation of TRAF3, a signaling
molecule downstream of pattern recognition receptors
(PRRs) required for IFN transcription. The imbalance of

An in vitro study also demonstrated that the delayed
IFNs response could be caused by the SARS-CoV-2
protein, ORF3b, that shown potently antagonized
human IFN-I activation (Konno et al, 2020). Supported
by a study, the high level of antibodies recognized
ORF3b in SARS-CoV-2 infection during the early
phase (Hachim et al, 2020). Another theory has been
reported that the profile of IFNs release is correlated with
STING (stimulator of IFN genes), an adaptor molecule
linking to the production of IFNs and NF-kB through
the sensing of cytosolic DNA. During early stage of
SARS-CoV infection, viral papain protease contained
in viral non-structural proteins interact with STING,
results in the downstream IFN secretion. In addition,
during the second phase of COVID-19, the activation
of STING leads to sudden IFN-β secretion and finally
induces the cytokine storm (Berthelot & Liote, 2020).
Therefore, various mechanisms to evade and suppress
IFNs explain the delayed IFNs response in the severe
condition of infection. The delayed impact interfere the
first line of immune response against viral infection and
sudden release of IFNs in the later phase following by
overproduction of cytokine and chemokines leading
to cytokine storm that involved in aggravation of the
disease, ARDS and organ damages.
COVID-19-induced cytokine storm is characterized by
elevated serum cytokine conditions, hyper inflammation,
cytopenia, the tendency for ARDS, blood clotting, and
increased serum concentration of ferritins (Henderson et
al., 2020). Cytokine storm is a condition of uncontrollable
overproduction of cytokine which thought to be caused
by aberrant immune activation, such as activation of
macrophages and other antigen-presenting cells in
attempt to notify the existence of virus to lymphocytes,
synthesis of pro-inflammatory factors during viral RNA
amplification inside the host cells, and viral invasion of
lymphocytes, evoking lymphocyte apoptosis (W. Luo et
al., 2020). One study in China also has been demonstrated
that the observation from 3,939 patients that both have
mild and severe degree of disease showed changes in
circulating leukocyte subsets and cytokine secretion from
normal condition (J. Wang et al., 2020). Besides, Huang
and colleagues reported that cytokine storms caused by
SARS-CoV-2 infection at Wuhan were characterized
with increased plasma concentrations of both Th1secreted cytokines (e.g., IL-1β, IFN-induced protein-10
(IP-10), macrophage chemoattractant protein-1 (MCP1),
and IFN-γ) that promote the inflammatory response,
and Th2-secreted cytokines (e.g., IL-4, IL-10) that
regulate the anti-inflammatory response. In principle,
the production of anti-inflammatory cytokines, mainly
E-ISSN 2477-0612
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is IL-10, represents one of the mechanisms involved in
balancing pro-inflammatory responses (Tisoncik et al.,
2012). However, some studies have revealed that even
though IL-10 is recognized as an anti-inflammatory
cytokine, it has positive correlation during lung fibrosis
when it was exposed to the lung in a high concentration
and a long time, as increased IL-10 expression was found
to induce collagen production and fibrocyte recruitment
into the lung (Sun et al., 2011). Remarkably, the
balance of pro- and anti-inflammatory cytokines play an
important role for maintaining lung immune homeostasis,
thus miss regulation one or more of these mechanisms
will lead towards the cytokine storm syndrome.In
addition, the high titer of coronavirus and abundance of
cytokines could promote the endothelial and epithelial
cells apoptosis that further may cause leak of pulmonary
vascular and alveolar edema, rendering to hypoxia
condition and ARDS (Ye et al., 2020). The cytokine
storm is also suggested to cause the extrapulmonary
multiple organ-failure (H. Wang & Ma, 2008). Hence,
the cytokine storm plays an important role in the
inflammatory response during coronavirus infections
leading to the ARDS and multiple-organ injury and thus
causing the severity of disease and death. It suggests
the treatment strategies to inhibit cytokine storm during
COVID-19 infection to prevent the progression of the
disease.
However, the use of inflammatory cytokine levels
and leukocytes level for diagnosis and monitoring of
cytokine storm in COVID-19 patients in clinical is
not yet standardized and currently limited for research
purposes only. Therefore, clinicians currently use more
common available inflammation biomarkers as an
early biomarker, which can predict COVID-19 disease
progression such as serum ferritin level, C-reactive
protein (CRP) level, and D-dimer level (England et
al., 2020; Henderson et al., 2020). Ferritin, an iron
storage protein, and C-reactive protein (CRP) are the
most widely used biomarker at hospital for monitoring
systemic inflammation. They are known as acute phase
reactants produced by liver during inflammation states.
Some clinical evidence have reported that ferritin and
CRP levels in patients with COVID-19 are reportedly
higher in patients with severe compared to moderate
disease, and in patients who died compared to those that
recovered (England et al., 2020; J. Wang et al., 2020)).
The other common biomarker being used is the D-dimer
level, a fibrin degradation product. It is usually used as
a test to check active clot formation and breakdown.
Even though not commonly used in the cytokine storm
disorders evaluation, D-dimer level has been reported
to correlate with disease severity in COVID-19, and the
value of D-dimer >1 μg/mL has remarked as one of the
earliest prognostic markers to predict patients with high
risk of mortality (England et al., 2020).
E-ISSN 2477-0612
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Potential of Cytokines Inhibitor for COVID-19
Treatment
Normally, when the cytokine is released, the function is
to give a signal to the immune system to eliminate the
virus as well as the infected alveolar cells. However, in
some cases, hyperproduction of cytokines will lead to
the aggressive immune response and led to the attack to
other healthy alveolar cells, which definitely worsens the
patient clinical outcome (Mehta et al., 2020; J. Wang et al.,
2020; Ye et al., 2020). In addition, vascular permeability
is increased by these pro-inflammatory cytokines, which
leads to fluid and blood cells hyper-flowing into the
alveoli, developing to respiratory failure, and even death
in a short time (Ye et al., 2020). Therefore, it is not a
surprise that some existed drugs that target the immune
response and block the CRS in COVID-19 patients have
become a potential target of recent clinical trials.
Ongoing Clinical Trials for Blocking the Cytokine
Storm in COVID-19
The monoclonal antibody or recombinant protein that
directed target key inflammatory cytokines are the
potential class of drugs to be evaluated for blocking
the cytokine storms in COVID-19 therapies. The level
of interleukin 2R (IL-2R), interleukin -1 (IL-1), and
interleukin 6 (IL-6) were reported to be positively
correlated with the disease severity in COVID-19 patients
(Chen et al., 2020). In addition, IL-6 was reported to be
significantly increased in patients with COVID-19 that
showed severe condition compared to non-severe and
associated with increased mortality in patients with
COVID-19 (Aziz et al., 2020) while IL-1 was reported
as biomarkers that associated with severity and fatal
outcomes of patients with COVID-19 (J. Wang et al.,
2020). Among many cytokines, Interleukin-6 (IL-6) and
Interleukin-1 (IL-1) appear to play an essential role in this
inflammation dysregulation through interrupting critical
inflammation pathways such as JAK-STAT and NF-kB
pathways, respectively (Zhong et al., 2020). Therefore,
some agents targeting these molecules become a center
of attention for the clinical studies.
Interleukin-6 (IL-6) Inhibitors
IL-6 is a member of the cytokine family that plays a vital
role in acute inflammation. It also has functions in cell
metabolism, cell differentiation, and immune regulation
(McGonagle et al., 2020). Almost all stromal and
immune system cells can generate this small polypeptide.
The production of IL-6 can be triggered during host
defense mechanisms by infectious or non-infectious
inflammation. In the classical cell signaling pathway,
IL-6 exerts its functions by binding to the IL-6 receptor
(IL-6R) and then activate some intracellular signaling
pathways such as JAK-STAT, YAP-TAZ, and PI3K-AKT
pathways (Zhang et al., 2020). The activation of these
pathways then promotes a more downstream process

5

Cytokine Storm in COVID-19

Pharm Sci Res, Vol 7 Special Issue on COVID-19, 2020

that regulates cell proliferation, cell differentiation, and
immune regulation (Liu et al., 2020). At the moment,
there are insufficient data from clinical trials using IL-6
inhibitors for COVID-19 patients. However, several
IL-6 inhibitors have now undergone the study for clinical
trials in patients with COVID-19, such as sarilumab and
tocilizumab.

Interleukin-1 (IL-1) Inhibitor
IL-1 is one of the pro-inflammatory cytokines and
the general name for two distinct proteins, IL-1α
and IL-1β, which their biological activities are often
indistinguishable. Generally, IL-1 has a function in
inflammation process during host defense mechanism
against infection, become an underlying mechanism of
fever and sepsis. The index between effective and toxic
functions of IL1 is known to be so narrow, hence the
regulation of IL-I in the human body is so tight. A miss
regulation of IL-1 will lead to several immune diseases.
Similar to IL-6, IL-1 also exerts its function after binding
with IL-1 receptor (IL-1R) and known to transduce and
activate one of the famous inflammation pathways, the
NF-kB pathway (Dinarello, 1997; Zhong et al., 2020).

Sarilumab
Sarilumab is a human IgG1 monoclonal antibody that
binds to both soluble and membrane-bound IL-6R; thus
could interfere signaling pathway induced by IL-6. It is
originally therapy approved by the FDA for rheumatoid
arthritis patients (McCarty & Robinson, 2018).
Regeneron Pharmaceutical, in collaboration with Sanofi,
now is in phase III of clinical trial testing sarilumab IV
injection (under Kezvara brand name) for hospitalized
patients with critical COVID-19 (NCT04315298).
There are positive trends in the initial results of
Phase II indicated by a decreased marker of systemic
inflammation such as, C-reactive protein (CRP) (which
changed by -79%, -77%, and -21% in the sarilumab 400
mg group, sarilumab 200 mg group, and placebo group,
respectively). However, final results are not yet published
since more patients are under recruitment (n:2500) for
phase III (U.S. National Library of Medicine, 2020).
Tocilizumab
Tocilizumab is a recombinant humanized monoclonal
antibody against IL-6R that is approved by the FDA for
rheumatoid arthritis and CRS induced by chimeric antigen
receptor T cell (CAR-T) therapy (Alten, 2011; Zhang et
al., 2020). Tocilizumab can be delivered by intravenous
(IV) or subcutaneous (SQ) injection. Nevertheless, for
the CRS therapy, the IV formulation should be used (Liu
et al., 2020; P. Luo et al., 2020). One clinical trial study
in France (n = 129) (NCT04331808) showed that the
number of hospitalized COVID-19 patients (moderate
to severe) who had died or who needed ventilation in a
group receiving tocilizumab IV injection was lower than
in the standard of care group. However, the final results
of the study have not been published yet (U.S. National
Library of Medicine, 2020). Another study of fifteenhospitalized COVID-19 patients in China had reported
that under-treatment of tocilizumab for seven days, the
serum level of IL‐6 tended to increase in the beginning
and then decreased after therapy in 10 patients followed
with the better clinical outcome. Unfortunately, a
persistent increase in IL‐6 was observed in four severely
critical patients who failed treatment. This study had
suggested that tocilizumab seems an effective treatment
option in COVID‐19 patients with a sign of cytokine
storms. However, the study is only limited in a few
numbers of patients and only use laboratory parameter
as assessment. Thus further study about the effectiveness
of tocilizumab in a larger number with more complete
clinical assessments is required (P. Luo et al., 2020).

Anakinra
The available drugs known could inhibit the binding of
IL-1 and IL-1R is anakinra, a recombinant human IL1R antagonist. It is originally therapy approved by the
FDA for rheumatoid arthritis patients and cryopyrinassociated periodic syndromes (Shakoory et al., 2016).
Several clinical trial studies of the anakinra use in
COVID-19 patients are ongoing in various countries, yet
there are no results have been reported (U.S. National
Library of Medicine, 2020).
Corticosteroids
For the treatment of COVID-19 inducedhyperinflammation, the attention also goes to the
corticosteroids
(i.e.,
prednisone,
prednisolone,
methylprednisolone, dexamethasone) which have
potent anti-inflammatory and antineoplastic functions.
Corticosteroids have been commonly used for several
disease therapy, such as allergy, autoimmune-related
diseases, asthma, and chronic obstructive pulmonary
disease (Rice et al., 2017). Therefore, it might be useful
to treat COVID-19 patients with acute lung injury and
ARDS caused by hyper inflammation in the lung (Mehta
et al., 2020). The minimum cost and the availability of
corticosteroids have added the potential of drugs to use
during this pandemic. Several reports have suggested the
positive results of corticosteroids used, remarkably in
severe hospitalized COVID-19 patients (Sanders et al.,
2020; Tang et al., 2020). Some studies for the clinical
trials are ongoing; thereby, the final data have not been
published yet (U.S. National Library of Medicine, 2020).
However, the benefit may also come with the higher side
effects, including delayed viral clearance and increased
risk of secondary infection which is shown by previous
studies in other viral pneumonia cases (Arabi et al.,
2018; Ni et al., 2019; Russell et al., 2020). Hence, it is
still cautious for using corticosteroids in COVID-19, the
treatment must be under tight diagnosis and assessment
from a physician and the use of high dose, long duration,
and multiple types should be avoided (Tang et al., 2020).
E-ISSN 2477-0612
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Promise of Mesenchymal Stem Cells and its
Derivative for the Treatment of COVID-19-Induced
Cytokine Storms
An alternative therapy in the clinical trial to combat
cytokine storm in COVID-19 patients is the use of stem
cell-based medicine. Among many stem cells available,
Mesenchymal Stromal/Stem Cell (MSC) is thought to be
the most suitable one.
MSC is tissue-derived multipotent stem cells with
proliferation capability, intrinsic differentiation
potential, and produce an abundance of therapeutic
growth factor and cytokines (Pittenger et al., 2019).
Depending on its local microenvironment, MSC could
promote or restrain inflammation through its cytokine
secretion onto immune sytem. Under activated immune
system, MSC would release pro-inflammatory cytokine
to promote inflammation, but when the immune system
is overactivated, MSC would switch to secrete antiinflammatory cytokine to suppress the immune effector
cells and activate the immune suppressor cells (Gao et
al., 2016; Jiang & Xu, 2020). According to International
Society of Cell Therapy, MSC is minimally defined to
possess three features: (1) plastic-adherent fibroblastlike morphology, (2) differentiation into “mesenchymal”
tissue lineages (mainly bone, fat, and cartilage), and
(3) presence or absence of specific cell surface markers
(Dominici et al., 2006). Of note, MSC-based cell
therapies have shown to be safe and promising for the
treatment of ARDS in early clinical trial setting (Zheng
et al., 2014). Hence, MSC-based treatment is expected to
be capable of not only act as an immunomodulator but
also to repair and regenerate lung tissue in COVID-19
patients with respiratory complications (Chrzanowski et
al., 2020).
In addition, Leng and colleagues reported the first pilot
of MSC transplantation in COVID-19 patients in China
with promising results (Leng et al., 2020). Specifically,
7 out of 10 patients received intravenous infusions of
clinical-grade allogeneic MSC, while the remaining three
patients received saline as a placebo control group. After
14-day observation, seven MSC-treated patients were
recovered whereas two of three patients in the placebotreated group (all placebo-treated patient is reported
to have a pre-existing condition) developed ARDS or
expired. Notably, a drop in systemic inflammation in the
MSC-treated group was observed with 10-fold lower
CRP level, lower TNF-α serum level, and increased IL10 serum concentration when compared with the placebo
group (Leng et al., 2020). While the result of this study
suggested that MSC treatment might be safe as suggested
with improvement of symptom and oxygen saturation
level within 2-4 days after MSC transplantation with
no hypersensitivity and no secondary infection were
observed and effective for COVID-19-induced cytokine
E-ISSN 2477-0612
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storm, it is essential to note that this study is limited by
its small number of included patient and lack of adequate
control groups.
In addition, the MSC product also has some limitations.
As therapeutic, MSC could contact the recipient blood,
so it is imperative that clinical use of MSC is required
to pass ISO109993-1/4 about its hemocompatibility/
biocompatibility with blood (Moll et al., 2019). An arising
concern on this issue is MSC expression of tissue factor
(TF/CD142/coagulation factor III), a glycoprotein that
could activate the extrinsic coagulation pathway, which
led to instant blood mediated inflammatory reaction
(Moll et al., 2019; Moll et al., 2020). Hence, infusions
of high TF/CD 142-expressing MSC products would rile
up the pro-thrombotic state of COVID-19 patients and
other diseases with hypercoagulability characteristics.
Another concern is that the lack of standardization
and careful characterization of various MSC-products,
since MSC isolated from different tissue demonstrated
different characteristics, for example: in bone repair
capacity (Kimura et al., 2014), TF expression (George
et al., 2018) and growth of brain tumor (Akimoto et al.,
2013).
Due to the limitation of cell-based therapy, extracellular
vesicles (EVs) have recently attracted attention and is
emerging as an alternative to cell-based therapy. EV
are a heterogeneous group of cell-derived membranous
structures comprising exosomes, apoptotic bodies, and
microvesicles, which originate from the endosomal
system or which are shed from the plasma membrane (van
Niel et al., 2018). Notably, recent paradigm shifts now
recognize EV as a means of intercellular communication
and involved in multiple biological processes, which
made them attractive for diagnostic or therapeutic
purposes. Compared to the whole-cell therapy, EVs are
thought to have several advantages, such as the lower
risk of tumorigenic effects, lower susceptibility to
damage by hostile disease microenvironment, contain
a combination of genetic cargo (protein, micro RNA,
mRNA, etc.), and the possibility for long-term storage.
Given the complexion COVID-19 disease, the fact
that MSC secretes various cytokine and chemokines
in a paracrine manner, and limitation of MSC, severe
COVID-19 patients is more amenable to treatment with
a pleiotropic agent like MSC-derived EV. Hence, in the
recent report, Sengupta et al. reported a prospective
non-randomized open-label cohort study on the use
of exosome derived from allogeneic bone marrowderived MSC at the early phase of the clinical trial
(Sengupta, 2020) in New York. In detail, 24 COVID-19
patients have received a single 15mL intravenous dose
of clinical-grade exosome derived from MSC. It is
noteworthy that 93% of patients reported having preexisting conditions. The authors reported that there is
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Figure 1. Schematic representation of the mechanism and potential therapy of cytokine storm in
COVID-19. SARS-CoV-2 is attached to the ACE2 receptor at the host’s cell membrane to enter the host
cells, and further perform its replication. Viral infection in the early stage induces delayed IFNs release
and accompanied by macrophage accumulation. Later, the chemokine was produced to attract more
macrophage, which secretes the high level of cytokines (cytokine storm), leading to ARDS. Suppressing
the cytokine storm is the therapy strategies to prevent the severity and mortality progression. SARSCoV-2: severe acute respiratory syndrome coronavirus 2; ACE2: angiotensin-converting enzyme 2; IFN:
interferon; ARDS: acute respiratory distress syndrome; IL-1: interleukin 1; IL-6: interleukin 6; MSC:
Mesenchymal stem cell.
no adverse effect related to exosome infusion after 72
hours. After 14-day observation, the author reported
a survival rate of 83%, with 71% patients recovered,
13% patient remained critically ill, and 16% of patients
were expired for reasons unrelated to the treatment. Of
importance, the patient’s oxygenation was improved, the
elevated number of neutrophils counts and improvement
of lymphopenia as marked with 192% increased average
pressure of arterial oxygen to fraction of inspired oxygen
ratio (PaO2/FiO2) and about 42%-46% increase of
average CD3+, CD4+, and CD8+ lymphocyte. On top
of that, serum levels of CRP, ferritin, and D-dimer were
also reported to be downregulated. Taken together, the
result of this study suggested that exosome derived
from MSC might be a better promising candidate to
treat severe COVID-19 patients owing to its safety,
oxygenation restoration properties, and downregulation
of cytokine storm marker. However, as with other early
report using MSC product, this study is limited by its
small sample size, lack of randomization and blinding,
only one exosome product were observed, and lack of
mechanistic approach of MSC-derived exosome.
Taken together, MSC and exosome derived from MSC
might be a promising candidate to treat severe COVID-19
patients owing to its safety and downregulation of
cytokine storms marker. Hence, further randomized

clinical trials for both MSC-based cell therapy and
MSC-derived EV products still needed to validate the
early promise of MSC and its derivative for a therapeutic
agent for COVID-19 associated cytokine storms.
Concluding Remarks
COVID-19 is caused by SARS-CoV-2 and quickly
became a pandemic threat. We are currently at the
beginning of understanding COVID-19 pathophysiology
and disease mechanism. Based on the current knowledge,
the cytokine storm is closely linked to the COVID-19
in severe conditions. As cytokines play an important
role in the inflammatory response, the uncontrollable
overproduction of cytokines could aggravate the disease
and lead to ARDS and multiple organ failure, even
resulting in death. Suppressing the cytokine storm may
be the potential to prevent the severity and mortality
rate in critically ill patients infected SARS-CoV-2.
Thus, a better understanding of cytokine storm-related
COVID-19 pathogenesis supports the development of
clinical management therapy.
Several clinical trials have been performed to explore
the potential therapy of COVID-19 related to cytokine
storms, such as inhibitor cytokine production (IL-1 and
IL-6 inhibitors), immunomodulator, and stem cell therapy
using MSC-based cell therapy and MSC-derived EV
E-ISSN 2477-0612

8

Pharm Sci Res, Vol 7 Special Issue on COVID-19, 2020

products (Figure 1). However, further clinical trials still
need to be explored to validate the potentials of abovementioned therapies in the management of COVID-19.
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